SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Millennium Pharmaceuticals, Inc. (MLNM)
An SI Board Since February 1997
Posts SubjectMarks Bans Symbol
3044 135 0 MLNM
Emcee:  icanpickem Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2619[VELCADE reduces infarction in rat models of focal cerebral ischemia] >>Ntuck-2/24/2006
2618pdf files myfilehut.com myfilehut.com myfilehut.com myfilehut.comlamamakara-2/18/2006
2617[Phase I Trial of Bortezomib in Combination with Docetaxel in Patients with Advatuck-2/17/2006
2616[Final SUMMIT time-to-event results, extended follow-up] >>Cancer. 2006 Ftuck-2/14/2006
2615[MLN-273/proteasome inhibition versus tuberculosis] >>Mol Microbiol. 2006tuck-2/14/2006
2614Item 1.01 Entry into a Material Definitive Agreement. On February 2, 2006, tIcebrg-2/6/2006
2613Curagen Up; Piper Upgrades On Multiple Myeloma Drug NEW YORK -(Dow Jones)- SIan@SI-2/6/2006
2612Morningstar Analyst Note 01-31-06 Millennium Pharmaceuticals' 2005 financialMLNM00-2/1/2006
2611citi: MLNM: In Line Quarter With Further Pipeline Disappointments mopgcw-1/31/2006
2610gs: MLNM (IL/N): On track for profitability in 2006 but sustainable growth unclemopgcw-1/30/2006
2609[Velcade versus liver fibrosis] >>Hepatology. 2006 Jan 26;43(2):335-344 [tuck-1/30/2006
2608Millennium Pharmaceuticals "neutral," target price raised Friday, JanIcebrg-1/27/2006
2607prjj^ov= ? Millennium provided Q4 financial results today posting higher total rMLNM00-1/26/2006
2606[Tipifarnib and Bortezomib Are Synergistic and Overcome Cell Adhesion-Mediated Dtuck-1/25/2006
2605[Velcade & HDAC inhibitor FK228 versus leukemia] >>Acta Haematol. 200tuck-1/22/2006
2604[PI/II trial for relapsed or refractory MM with melphalan & velcade] >&gtuck-1/19/2006
2603[Perifosine augments dexamethasone, doxorubicin, melphalan, and bortezomib-inductuck-1/19/2006
2602With that AE incidence being negligible around the world yet 4 reports with 2 deIan@SI-1/13/2006
2601posted by rob_cos on yahoo late last nite. anyone have thoughts on what to make software salesperson-1/13/2006
2600SUMMARY ? Celgene announced today 2006 expense guidance projecting 20%-25% y/y iMLNM00-1/10/2006
2599One has to wonder why UBS even bothered wasting the paper on this reit and priceIan@SI-1/9/2006
2598I suppose so; a patient could do without Vitamin C supplementation for a while, tuck-1/9/2006
2597RE: <i>[Vitamin C Inactivates the Proteasome Inhibitor PS-341 in Human CanIan@SI-1/9/2006
2596[MOA of Velcade in bone marrow antiangiogenesis] >>Cancer Res. 2006 Jan 1tuck-1/8/2006
2595[Bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivotuck-1/8/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News